Dr. Anthony B. Morlandt, Assistant Professor Department of Oral and Maxillofacial Surgery of the University of Alabama at Birmingham, joins Proteocyte AI’s Clinical Advisory Board

Toronto, ON; June 12, 2018 – Proteocyte AI, a company designing tests that predict the progression of premalignant lesions, announced today that Dr. Anthony B. Morlandt, Assistant Professor, Chief Oral Oncology, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, has joined the Company’s Clinical Advisory Board.

“We are delighted to have Dr. Morlandt join our Clinical Advisory Board as he brings significant scientific knowledge and expertise to Proteocyte AI,” said John Davis, President and CEO of Proteocyte AI. “Our Clinical Board will provide relevant insight and guidance as we move to our next stage of development, focused on commercialization and market expansion to fuel global growth.”

Proteocyte AI is focused on combining artificial intelligence and protein biomarkers to determine a patient’s five-year risk progression. This technology predicts who is at risk to develop cancer before they actually have cancer. Proteocyte AI’s Straticyte™ is a test that predicts the progression of premalignant oral lesions.

“Straticyte has the potential to significantly change outcomes for patients by providing more relevant information about dysplastic oral lesions. Currently there is a gap in predictive tools for healthcare professionals,” said Dr. Morlandt. “I am pleased to join the Clinical Advisory Board of Proteocyte AI and look forward to working with the other members of the board and management.”

Dr. Morlandt, MD, DDS, FACS, serves as Chief of the Section of Oral Oncology within the Department of Oral and Maxillofacial Surgery at University of Alabama at Birmingham (UAB) Medicine and is a full time academic head and neck surgeon. He is Director of the Head and Neck Oncology Fellowship program at UAB. Dr. Morlandt is an Associate Scientist in the Cancer Chemoprevention Program with the UAB Comprehensive Cancer Center. In 2015, Dr. Morlandt received the AAOMS Faculty Educator Development Award and has been inducted into the American Head and Neck Society and is a Fellow of the American College of Surgeons. He is also a Diplomate of the American Board of Oral and Maxillofacial Surgery. Dr. Morlandt graduated from Baylor University and completed his DDS magna cum laude at the University of Texas Health Sciences Center in San Antonio, Texas, He received his MD and internship and residency in Oral and Maxillofacial Surgery from the University of Alabama School of Medicine. Dr. Morlandt then went on to complete a fellowship in head and neck oncology and microsurgery at the University of Florida College of Medicine in Jacksonville, Florida. Dr. Morlandt has authored several peer reviewed scientific articles and textbook chapters.

Straticyte enables healthcare professionals to customize patient treatment, improving outcomes for patients at risk for developing cancer, while reassuring those patients who have minimal to no risk of disease progression. The test can be easily incorporated into clinical practice as no additional tissue samples are needed for assessment. Straticyte is currently being offered on a complimentary basis until August 1, 2018.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.